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ABSTRACT 
More than 50% of patients with advanced stages of colon cancer suffer from progressive loss of 
skeletal muscle, called cachexia, resulting in reduced quality of life and shortened survival. It is 
becoming evident that reactive oxygen species (ROS) regulate pathways controlling skeletal 
muscle atrophy.  Herein we tested the hypothesis that antioxidant supplementation could prevent 
skeletal muscle atrophy in a model of cachectic Colon 26 (C26) tumor-bearing mice. Seven-
week-old BALB/c mice were subcutaneously inoculated with colon 26 (C26) cancer cells or 
PBS. Then C26-mice were daily gavaged during 22 days either with PBS (vehicle) or an 
antioxidant cocktail whose composition is close to that of commercial dietary antioxidant 
supplements (rich in catechins, quercetin and vitamin C). We found that antioxidants enhanced 
weight loss and caused premature death of mice. Antioxidants supplementation failed to prevent 
(i) the increase in plasma TNF-α levels and systemic oxidative damage (ii) skeletal muscle 
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atrophy and (iii) activation of the ubiquitin-proteasome system (MuRF-1, MAFbx and 
polyubiquitinated proteins). Accordingly, immunohistological staining for Ki-67 and the 
expression of cell cycle inhibitors demonstrated that tumor of supplemented mice developed 
faster with a concomitant decrease in oxidative damage. Previous studies have shown that the use 
of catechins and quercetin separately can improve the musculoskeletal function in cachectic 
animals. However, our results indicate that the combination of these antioxidants reduced 
survival and enhanced cachexia in C26-mice.  
Keywords:  
muscle wasting, TNF-α, myostatin, tumor growth, oxidative stress 
 
INTRODUCTION 
Cachexia is a multifactorial syndrome and a complex metabolic disorder that manifests mainly in 
patients with diabetes, acquired immune deficiency syndrome (AIDS) and cancer.  It is 
characterized by a continuous loss of muscle mass with or without depletion of adipose tissue [1]. 
Contrary to anorexia, in which adipose tissue is mainly affected but rarely the muscle 
compartment, conventional and single-nutritional intervention failed to prevent total weight loss 
and/or restore lean body mass in cancer cachexia [2]. Patients with advanced stages of colon 
cancer are mainly affected by cachexia, which accounts for more than 20% of mortality in total 
cancer patients [3]. Muscle atrophy is one of the most significant clinical events in cancer 
cachexia that negatively impact patient’s quality of life and strongly reduce anti-cancer treatment 
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efficiency [4]. Cachexia-induced muscle atrophy (CIMA) is often associated with psychosocial 
effects due to functional impairment and a dramatically reduced physical activity in cachectic 
patients [5]. Therefore, the management of cancer cachexia, notably muscle atrophy, represents a 
real challenge and a major issue for researchers and clinicians in the biomedical field. 
Disease-related muscle atrophy have received much attention during the past decade and several 
studies have been devoted to understand the pathophysiology and explore the underlying 
molecular mechanisms involved in the wasting process. Muscle atrophy is mainly due to an 
increase in protein catabolism associated with hypo-anabolism, resulting in a net decrease in 
overall muscle mass [6]. High circulating levels of tumor-derived factors (e.g. Tumor Necrosis 
Factor-α and Interleukin-6) and some Transforming Growth Factor-beta (TGF-β) family ligands 
(e.g. myostatin and activin), are responsible for the inhibition of the anabolic/hypertrophic, 
Phosphoinositide 3-kinase (PI3K)-Akt pathway and subsequently the depression in protein 
synthesis rate [7, 8]. On the other hand, these cytokines, trigger the activation of 
catabolic/atrophic upstream signaling cascades (e.g. Nuclear Factor-κB /AP-1), leading to the 
transcriptional activation of two muscle-specific E3 ubiquitin-ligases, known as, Muscle Ring 
finger protein-1 (MuRF-1) and Muscle Atrophy F-box (MAFbx) [9, 10]. Sarcomeric proteins 
destined to degradation are tagged with polyubiquitin chain, thanks to MuRF-1 and MAFbx, prior 
the entry into the proteasome core, where they undergo degradation into small peptide fragments. 
Hyper-activation of the ubiquitin-proteasome proteolytic system is common in CIMA and is 
mainly responsible for the high breakdown of myofibrillar proteins [11].  
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Currently, it is well established and recognized that muscle wasting is intimately linked to 
oxidative stress (OS) in various conditions including disuse, ageing and spinal cord injury [12, 
13]. It seems that OS is also implicated in cachexia pathogenesis, since oxidative damage 
markers (e.i. carbonyls proteins) were increased in the skeletal muscle of cachectic patients with 
lung cancer and were positively correlated with muscle proteolysis [14]. Furthermore, Reactive 
Oxygen Species (ROS) have been proposed to act as a second messenger to activate the 
ubiquitin-proteasome system in an in vitro model of muscle atrophy [15]. Actually, there is 
growing evidence that sarcopenia or disuse-induced catabolic state in the muscles of rodents 
models, could be prevented or delayed by the use of different types and doses of antioxidants 
such as Vitamin E, Resveratrol, Cystein-based antioxidants and Allopurinol [16-19]. Since a 
broad range of ROS is involved in cachexia-related muscle atrophy pathogenesis, we suppose 
that the use of a combination of antioxidants could be more valuable to target a large spectrum of 
these species and limit their detrimental activities. Herein, we tested our hypothesis in a model of 
colon 26 (C26) tumor-bearing mice supplemented or not with a mixture of antioxidants 
containing mainly, catechins, curcumin, quercetin and vitamin C.  
 
MATERIALS AND METHODS 
Animals care and protocol  
All experiments were approved by the Regional Ethics Committee for Animal Experimentation 
of Brittany (N°R-2012-AR-01) and conducted in accordance with the current ethical standards of 
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the European Community (Directive 2010/63/EU). Seven-week-old male Balb/c mice were 
obtained from Janvier Labs (Le Genest Saint Isle, France) and housed in the Animal Care Facility 
of the laboratory “Movement, Sport and health Sciences” accredited for live animal 
experimentation (N°A35-047-34, delivered by the Department of Veterinary Services, French 
Ministry of Agriculture). Mice were maintained on a 12:12-h dark-light cycle. Water was 
available ad libitum and standard laboratory chow was provided, changed and monitored daily. 
The animals were divided into three experimental groups: control group that received a daily 
supplement of 250 μl of PBS (n=10); C26 tumor-bearing group that received 250 μl of PBS 
(n=10); and C26 tumor-bearing group that was daily supplemented with an antioxidant mixture 
rich in catechins, curcumin, quercetin and vitamin C (81.5 mg/kg of body weight) dissolved in 
350-500 μl of PBS (n=10). The volume of the daily supplement received by each mouse in this 
group was daily adjusted with body weight change. All treatments were administrated by oral 
gavage. The composition of the antioxidant cocktail is presented in Table 1. Twenty two days 
after inoculation of C26 cells or when mice have lost more than 20% of body weight, animals 
were anesthetized with a ketamine-xylazine-butorphanol cocktail. Soleus, Extensor digitorum 
longus (EDL), rectus femoris, gastrocnemius (Gas) muscles and tumor were weighed and 
immediately frozen in liquid nitrogen or fixed in 4%-paraformaldehyde (PFA).  Venous blood 
was collected into EDTA tubes and centrifuged (1500 g, 10 min, 4°C) for plasma collection.  
 
Culture of C26 cell line and inoculation 
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Frozen C26 colon cancer cells were obtained from Cell Lines Service (CLS, Eppelheim, 
Germany). The murine tumor cells were maintained in a humidified atmosphere at 37°C and 5% 
CO2 and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 
mM L-glutamine (Life technologies, Saint Aubin, France). Cells were collected using 0.25% 
trypsin-EDTA. Before the injection of C26 cells into mice (day 1), cells were counted using a 
hemocytometer, pelleted via centrifugation (500 g, 5 min, 25°C) and resuspended at 1x106 C26 
cells/ml of sterilized PBS. Mice were shaved on the dorsal side and given a subcutaneous 
injection of either 1x106 C26 cells suspended in 100 μl of sterilized PBS or 100 μl of sterilized 
PBS only (control) [20, 21]. Body mass was monitored daily after inoculation. 
Determination of cachexia symptoms severity 
Mice were classified as having mild, moderate, or severe cachexia based on their body mass and 
gastrocnemius muscle mass. C26 tumor-bearing mice were categorized as having mild cachexia, 
if both variables were within 1 SD (Standard Deviation) of the mean of control mice. Mice with 
severe cachexia were > 2 SDs away from the mean of control mice [22]. 
Wire hang test 
At the beginning of the protocol, 10 days and 22 days after inoculation, a wire test was used to 
assess whole body force. Mice were placed on top of a wire cage lid that was shaken gently 3 
times, causing the mouse to grip the wire. Then, the wire cage lid was inverted. Three trials per 
animal were performed for each evaluation and the best time of latency was retained to calculate 
the holding impulse [23]. 
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Histological analysis 
EDL muscle or tumor samples were 24h PFA-fixed and paraffin-embedded in blocks. Serial 
transverse sections of 4 μm were obtained from each sample using a LEICA microtome and were 
mounted on glass slides, three cuts in each. The cuts were performed in the wider part of the 
tissues. Subsequently, EDL sections were stained for reticulin using the Gomori method to 
measure muscle fibers diameter and tumor sections were stained for Ki-67 in order to determine 
the percentage of tumor proliferating cells. All the histological sections were scanned (20× 
objective and 40× magnification).  The minimal Feret’s diameter of muscle fiber was determined 
using the Image J software. Mean fiber diameter for each muscle was determined from at least 
150 fibers per muscle. For ki-67 quantification four images were taken per section and the 
number of ki-67 positive nuclei was counted using NDP image software. 
RNA isolation and RT-qPCR 
Total RNA were extracted from Gas muscles and tumor tissues using Trizol® reagent according 
to the manufacture’s protocol (Sigma Aldrich). RNA amount and integrity was determined and 
analyzed using RNA stdsens chips (700-7153) and Experion automated electrophoresis station 
(Bio-Rad, France). All samples were of high RNA quality after electrophoresis on agarose 
FlashGel system (Lonza, France). 1μg of total extracted RNA was used to perform the Reverse 
Transcription (RT) reaction (IScript reverse transcription, 170-8840). Sybergreen real-time PCR 
was carried out in a final volume of 10 μl per reaction containing: 5μl of neo-synthetized cDNA 
(diluted at 1/5), 0.2 μl of primer pair at 10 μM each (Sigma Aldrich and Integrated DNA 
Technologies) and 4.8 μl of GOTaq® qPCR Master Mix (A6001, Promega, Madison, USA). All 
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experiments were monitored in a CFX Real-Time system (Bio-Rad, Marnes-La-Coquelle, 
France). The expression of target genes (MuRF-1, MAFbx, TNF-α and IL-6) was normalized to 
the reference genes 18S or HPRT1 and the relative expression was calculated using the ΔΔCt 
method. The following primer sequences were used:  
Trim-63 (F: ACATGGACTACTTTA-CTCTGG and R: CATTGGTGGTTCTTTACCC);  
Fbxo32 (F: CTGAAAGTTCTTGAAGA-CCAG and R: GTGTGCATAAGGATGTGTAC); 
Rn18S (F: CAGTTATGGTTCCTTTGGTC and R: TTATCTAGAGTCACCAA-GCC);  
TNF-α (F: CCAGACCCTCACACTCAGATCA and R: CACTTGGTGGTTTGCTACGAC); 
IL-6 (F: ACTTCCATCCAGTTGCCTTCT and R: GAATTGCCATTGCACAACTCT); 
HPRT1 (F: ACGCCAGACTTTGTTGGATTT and R: CAGGACTCCTCGTATTTGCAG). 
Western blot analysis 
Total proteins were extracted from Gas muscles and tumor tissues in a lysis buffer containing 50 
mM Tris-HCl, 10 mM EDTA, 1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 50 mM NaF, 
100 μM sodium orthovanadate and proteases inhibitors cocktail (Sigma P8340, 5 μl/ml). The 
samples were homogenized using a Polytron homogenizer at 4°C. Each sample was then 
incubated on ice for 30 min followed by 3 x 10 s of sonication. The homogenates were 
transferred to microcentrifuge tubes and centrifugated at 12000 g for 12 min at 4°C. The protein 
concentration of the supernatant was determined by a Lowry assay using a serial dilution of 
bovine serum albumin (BSA) to draw the standard curve. Samples were then diluted in SDS-
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PAGE sample buffer [50 mM Tris·HCl, pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 
and 0.1% bromophenol blue], and heated 5 min at 95°C. Samples containing 40-100 μg of 
proteins were resolved on 10-15% SDS-PAGE. The proteins were transferred at 240 mA for 90 
min onto a 0.2-μm nitrocellulose membrane. Membranes were blocked with 5% BSA or nonfat 
dry milk in TBST (Tris-buffered saline/0.1% Tween-20) for one hour at room temperature (RT). 
Membranes were incubated overnight at 4°C with the appropriate primary antibodies: anti-
phospho-AKT (9271S), anti-AKT (9272S), anti-phospho-NFκB (p65) subunit (3033S), anti-NF-
κB (p65) subunit (8242S), anti-ubiquitin (3933S), anti-p21 (2947S) and anti-p27 (2552S) 
(1:1000; Cell Signaling, Ozyme, Saint Quentin-Yvelines, France); anti-catalase (sc-50508) and 
anti-HSC70 (sc-7298) (1:2000; Santa Cruz technologies, Santa Cruz, CA, USA); anti-MnSOD 
(ADI-SOD-110-F; 1:500; Enzo Life Sciences, Lyon, France) and anti-CuZnSOD (6F5; 1:2000; 
Novus Biologicals, Bio-techne, Lille, France); anti-α-sarcomeric actin (A2172; 1:5000; Sigma 
Aldrich) . Blots were washed with TBST and incubated for one hour at RT with infrared dye-
conjugated secondary antibodies (LI-COR, Lincoln, NE, USA). After washing, blots were 
scanned using the Odyssey Imaging System (LI-COR, Lincoln, NE, USA). Densitometry analysis 
of the bands was conducted using GS-800 Imaging densitometer and QuantityOne software. 
Phospho-specific signal was normalized to the total signal to estimate the ratio of activation. 
Enzyme Linked Immunosorbent Assay (ELISA) 
Plasma myostatin levels were detected using Quantikine® ELISA kit purchased from R&D 
systems (DGDF80, R&D systems Europe, Lille, France). Briefly, 20μl of mouse plasma samples 
were activated by adding 10 μl of 1N Hcl and neutralized with 10 μl of 1.2 N NaOH/0.5M 
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HEPES. Then the pH of neutralized samples was measured to ensure that it is within 7.2 and 7.6. 
Plasma samples were added to a 96 wells plate pre-coated with capture monoclonal antibody 
specific to myostatin. A detection antibody linked to a peroxidase enzyme was next added to each 
well. Finally, a substrate solution was added and color developed in proportion with the amount 
of myostatin bound in the initial step. Color change was measured at 450 nm using a microplate 
reader. Plasma TNF-α concentrations were determined using a mouse TNF-α detection kit 
according to the manufacture’s protocol (430907, LEGEND MAXTM, BioLegend) 
Oxygen Radical Absorbance Capacity assay (ORAC) 
Total antioxidant capacity was measured by spectro-fluorometry. A mixture containing: 0.5 M 
perchloric acid (Prolabo), 100 mM PBS and 100 μL of plasma was centrifuged at 3000g for 5 
min at 4°C. The pH of the obtained supernatant was adjusted to ~7 with a solution of 5 M NaOH 
and 50μl of supernatant were added into each well in a 96-well plate. Then, 14 μM of fluorescein 
(Fluka) and 17.2 mg/ml of 2,2'-azobis (2-aminopropane) dihydrochloride (AAPH) were 
dispensed, into each well. Fluorescence was recorded for 60 min at excitation and emission 
wavelengths of 485 and 530 nm, respectively, using a microplate reader. Calibration solutions of 
Trolox were also tested to establish a standard curve. 
Protein carbonylation 
Analysis of protein carbonyl levels was performed using an oxyblot kit according to the 
manufacture’s protocol. (S7150; Millipore, Île-de-France, France). Protein extracts (10 μg) were 
derivatized with 1% DNPH for 15 min at RT and then separated on 12.5% SDS-PAGE. After 
transfer, membranes were blocked with 1%BSA in PBST (Phosphate Buffered Saline/0.05% 
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Tween-20) and then incubated overnight at 4°C with anti-DNP primary antibody (1:100) supplied 
with OxyBlot kit. After washes, secondary IgG goat anti-rabbit antibody (IRDye 680; LI-COR, 
Lincoln, NE, USA) was added for one hour in the dark at RT. Membranes were scanned using 
Odyssey Infrared Imaging System. 
4-Hydroxy-2-nonenal analysis 
Detection of 4-hydroxy-2-nonenal (4-HNE) adducts, was performed as described previously [24]. 
Briefly, membranes were incubated in a solution of 250 mM sodium borohydride in 100 mM 
MOPS, for 15 min at RT, immediately after transfer. Then, were incubated overnight at 4°C with 
primary antibody, specific for 4-HNE, which was kindly provided by Pr. Luke Szweda (OMRF, 
Oklahoma City, OK, USA). Membranes were washed with PBST and incubated for one hour at 
RT with secondary IgG goat anti-rabbit antibody (IRDye 680; LI-COR, Lincoln, NE, USA). 
After washing, membranes were scanned using the Odyssey Imaging System. 
Statistical analysis  
Median survival was determined by the Kaplan-Meier method and analyzed by the log-rank test. 
Other results are presented as means ± Standard Error Mean (SEM). Significance of intergroup 
differences was examined using Student t-test for tumor comparisons or One-way analysis of 
variance (ANOVA) for muscle and plasma comparisons. Normality and equal variance were 
checked before the statistical analysis was conducted. Significant main effects or interactions 
were further analyzed by the Fischer LSD post hoc test. If normality of the data was not present, 
the data were analyzed using an ANOVA on ranks, and further analyzed by the Dunn’s test. For 
all statistical analyzes, the level of significance was set at P < 0.05. 
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RESULTS 
Antioxidant supplementation enhanced colon cancer cachexia development and caused 
premature death 
To assess the effect of antioxidant supplementation on cancer cachexia development, we 
supplemented C26-mice, an experimental model widely used to study cancer cachexia, with a 
mixture of antioxidants or PBS, as described above. Surprisingly, we found that body weight of 
supplemented animals (C26-Antiox) started to decrease at 10th day post injection, whereas C26-
PBS mice presented significant body mass reduction only after 20 days post injection (Figure 
1A). When mortality started to occur in C26-mice groups, body weight measures were no more 
taken into account in data interpretation, which explains why body weight measures were stopped 
at 13th and 20th days for C26-Antiox and C26-PBS mice, respectively. Here, we showed that 
antioxidant supplementation caused 50% and 100% of C26-mice deaths at 18 days and 22 days 
post injection, respectively. In comparison, only 20% of C26-PBS mice died after 22 days 
(Figure 1B). Furthermore, neither C26-PBS nor C26-Antiox mice developed anorexia since no 
change in food intake was observed in both groups compared to control group (Figure 1C). 
Based on various criteria of cancer cachexia development (see Materials and Methods), we found 
that all supplemented mice developed severe cachexia, while C26-PBS mice were distributed 
between mild, moderate and severe cachexia (Figure 1D). These results demonstrated that 
natural antioxidants enhanced colon cancer cachexia development and caused premature death in 
C26-mice. 
Cachexia-induced muscle wasting was not prevented with antioxidants 
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Next, we investigated whether muscle wasting was modulated with antioxidants. As depicted in 
Figure 2C, both C26-PBS and C26-Antiox mice exhibited lower muscles weight compared to 
control mice (except for soleus). Remarkably, EDL and Gas muscles weight of C26-Antiox mice 
were significantly lower than those of C26-PBS mice (6.6 ± 1.3 and 79.4 ± 10.8 mg, respectively, 
vs. 8 ± 1.4 and 94.5 ± 11.3 mg, P<0.001, Figure 2C). Figure 2A shows EDL muscle sections 
stained for reticulin with the Gomori method. We observed that fibers diameter of both C26-PBS 
and C26-Antiox-mice were lower than control group (29.8 ± 5.8 and 28.9 ± 3.1 μm, respectively 
vs. 41.2 ± 3.1 μm, P<0.05, Figure 2B).  A hanging wire grip test was also performed to 
determine how C26 tumor and antioxidants affect animals’ muscle strength.  Interestingly, the 
impulse score decreased dramatically in C26-PBS and C26-Antiox mice (6.32 ± 1.81 and 3.85 ± 
2.14 N.sec, respectively) compared to control (18.47 ± 7.11 N.sec; Figure 2D) at 22 days or 
when mice reached 20% of body weight loss. No difference in impulse score was observed 
between the three groups at 10th days post-injection. Contrary to our speculations, antioxidant 
complements were unsuccessful to slow muscle wasting. 
Antioxidants suppressed Akt activation but failed to block ubiquitin-proteasome system 
induction 
Tumor Necrosis Factor-α (TNF-α) and Myostatin (Mstn) are two mediators known to play a key 
role in the wasting process. We found that circulating TNF-α levels were up-regulated in both 
C26-PBS and C26-Antiox groups (10.52 ± 2.63 and 7.5 ± 2.23 pg/mL respectively, P<0.001) 
compared to control (2.17 ± 0.34 pg/mL; Figure 3A). Whereas the relative expression of TNF-α 
and IL-6 transcripts in Gas remained unchanged between all three experimental groups (Figure 
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S1). Counterintuitively, plasma Mstn levels were drastically decreased in C26-PBS compared to 
control (16819 ± 4283 vs 41464 ± 5418 pg/mL). This decrease was more pronounced in C26-
Antiox (10603 ± 2523 pg/mL; Figure 3B). Furthermore, we found that Mstn levels were 
positively correlated with Gas muscle mass (r=0.91, P<0.05). Gas muscles were used to perform 
western blotting and RT-qPCR analysis. Interestingly, Akt activation (ratio phospho-Akt/Akt 
total), a marker of protein synthesis, was down-regulated only in antioxidants-supplemented mice 
comparing to C26 and control (-77%, P<0.05, Figure 3D). The phosphorylation of Nuclear 
Factor-κB (NF-κB) on the p65 subunit was up-regulated in C26-PBS and C26-Antiox mice 
(+141% and +54% respectively, P<0.001; Figure 3C). Although, p65 was phosphorylated to a 
lesser extend in supplemented comparing no-supplemented mice, the difference between both 
groups was not statistically significant. At the mRNA level the relative expression of MAFbx and 
MuRF-1, was flagrantly increased in both C26-PBS (7.6 and 4.7 fold, P<0.001) and C26-Antiox 
(7.5 and 4.5 fold, P<0.001) comparing to control (Figure 3E). Accordingly, protein 
ubiquitination was increased in both groups of C26 (+29% and +26%, respectively, P<0.05; 
Figure 3F). Taken together, these data suggest that antioxidants decreased plasma Mstn levels, 
depressed Phospho-Akt expression and failed to prevent ubiquitin-proteasome system activation. 
 
Antioxidants exerted a pro-oxidant effect in skeletal muscle of C26 mice 
As shown in Figure 4A, we observed that C26-Antiox mice exhibited higher carbonylated 
proteins levels compared to control animals (+63%; P<0.001). Interestingly, no change was 
observed in C26-PBS mice when compared to control. Contrary to carbonylated proteins, no 
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change in the protein content of 4-HNE, a marker of lipid peroxidation, was detected between the 
three experimental groups (Figure 4B). Expression of the antioxidant enzymes, magnesium 
superoxide dismutase (MnSOD) and copper-zinc superoxide dismutase (CuZnSOD) remained 
unchanged between all groups of mice (Figure 4C). While, catalase expression was significantly 
higher in C26-PBS and C26-Antiox (+70% and + 71% respectively; P<0.01; Figure 4C) 
compared to control. These data indicate that antioxidant supplementation could up-regulate, in 
part, oxidative damage in skeletal muscle ongoing atrophy.  
C26-Antiox mice exhibited a paradoxical reduction in systemic antioxidant capacities  
As patients with colorectal cancer exhibit systemic OS [25, 26], we hypothesized that antioxidant 
supplementation in our experimental model of colon cancer could reduce systemic oxidative 
damages. We observed that C26-PBS and C26-Antiox mice exhibited systemic OS (Figure 5B 
and C), as evidenced by the increase of plasma carbonylated proteins content (+85 and +65% vs. 
control mice respectively; P<0.01, Figure 5B) and 4-HNE (+172.5 and +180 % vs. control mice 
respectively; P<0.001, Figure 5C). However, no significant change in protein carbonyl and 4-
HNE content was detected between C26 and C26-Antiox mice. We next determined total 
antioxidant capacities in plasma, using the ORAC test.  Total antioxidant capacities of C26-mice 
did not significantly differ from those of control mice (1315 ± 343 vs. 1479 ± 196 μmol eq 
Trolox/L). Unexpectedly, this parameter decreased drastically (P<0.001) in C26-Antiox mice 
compared to control and C26-PBS mice (1479 ± 196 vs. 823 ± 174 μmol eq Trolox/L, P<0.001 
Figure 5A). These results suggest that the antioxidant cocktail decreased the total antioxidant 
capacities without impacting systemic OS in C26-mice. 
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Antioxidants accelerated tumor growth and reduced tumor lipid peroxidation 
To understand if the deleterious effects observed previously in supplemented mice were tumor-
dependent, we analyzed the effects of antioxidant supplementation on tumor growth and OS. We 
observed that tumor weight did not differ between both C26-PBS and C26-Antiox mice (Figure 
6A). Furthermore, Ki67 staining, a marker of proliferation rate, was significantly higher in C26-
Antiox mice compared to C26-PBS (+ 14.3%, P<0.01; Figure 6B and C). However, we highlight 
that tumor weights were early reached in C26-Antiox mice since these animals presented a 
median survival of 18 days, whereas this median was not reached in C26-PBS mice within 22 
days when all C26-Antiox mice were died (see Figure 1B). These results suggest that antioxidant 
supplementation enhanced C26 tumor growth in our experimental model. In line with this 
hypothesis, we focused on tumor proliferation and cell cycle regulation. We found that the 
expression of p21 but not p27, two inhibitors of cell cycle, was down-regulated in tumor of C26-
Antiox mice when compared to C26-PBS mice (-45%, P<0.05, Figure 6D). To determine how 
antioxidant can modulate oxidative damage in tumor, we quantified 4-HNE and carbonylated 
proteins. No significant difference in carbonyled proteins content was denoted between C26-PBS 
and C26-Antiox mice (Figure 6E). We found that 4-HNE content was markedly lower in tumors 
of supplemented animals compared to C26-PBS mice (-66%, P<0.001; Figure 6F). Ultimately, 
local inflammation within tumor seemed to be unaffected in response to antioxidant 
supplementation, as evidenced by the unchanged expression of TNF-α and IL-6 at the mRNA 
level (Figure S1). All these data would finally support the paradigm, that antioxidants accelerate 
tumor proliferation and modulate OS profiles within tumor. 
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DISCUSSION 
Cancer cachexia is a devastating disorder that developed in 50-80% of patients with advanced 
stages of cancer. Common symptoms are: anemia, hypogonadism, systemic inflammation, 
respiratory failure, heart atrophy, altered liver metabolism, adipose tissue depletion and excessive 
loss of skeletal muscle [27-29]. Although muscle wasting, the key feature of cachexia, is mainly 
responsible for the death of many cancer patients, it remains a poorly understood mechanism. 
Several pieces of evidence suggest that OS is involved in the establishment and evolution of this 
catabolic process [30]. In the present study we demonstrated that supplementation with 
antioxidants reduced mice survival, failed to prevent muscle atrophy and promoted tumor growth 
in C26 tumor-bearing mice.  
We found that antioxidants accelerated cachexia development and reduced life span in C26 mice. 
To our knowledge no studies have assessed the effects of antioxidant supplementation on the 
survival rate of cachectic animals. Nevertheless, recently, a meta-analysis concluded that the 
results of intervention studies with antioxidants, performed from 1966 till 2009, have no effects 
on colon cancer incidence and recurrence [31]. Even worse, they found that combination of β-
carotene with other antioxidants was associated with an increase in mortality.  
Elevated systemic levels of TNF-α, Interleukine-6 and Interferon-γ have been reported in patients 
experiencing cachexia and in several rodent models of cancer cachexia [32-35]. There is 
considerable evidence that TNF-α plays a pivotal role in muscle loss during cancer cachexia. 
Thus transplantation of Chinese Hamster Ovary cells, transfected with human TNF-α gene, in 
nude mice produced a syndrome resembling to cachexia [36].  In our model the circulating levels 
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of TNF-α were significantly higher in C26 mice supplemented or not with antioxidants. The 
unchanged expression of TNF-α within Gas muscles is not surprising, as usually skeletal muscle 
is not a major source of cytokines production during cachexia but rather undergo catabolism in 
response to tumor-derived cytokines. TNF-α induces the activation of NF-κB, leading to the 
induction of the ubiquitin-proteasome system [37]. We found that the p65 subunit of NF-κB was 
phosphorylated on the Ser536 residue, notably, in muscles of no-supplemented mice. The 
decrease of p65 phosphorylation levels observed in supplemented animals did not result in the 
reduction of MAFbx and MuRF-1 mRNA relative expression and protein ubiquitination, 
indicating that the ubiquitin-proteasome system was activated regardless the phosphorylation 
status of p65. Additionally the expression of IKB-α, the specific inhibitor of NF-κB, remained 
unchanged in skeletal muscle of the three experimental groups (data not shown). This may 
suggest the existence of other compensatory mechanisms, than NF-κB signaling, which promote 
proteasome system induction. Our interpretation is consistent with the findings of a recent report, 
showing that p65 binding to DNA is not required for the regulation of genes expression involved 
in the development of muscle atrophy in cachectic mice bearing C26 tumor [38]. Moreover, 
antioxidants have not only failed to slow the catabolic process but they, most likely, aggravated 
muscle wasting by suppressing Phospho-Akt expression, which is directly involved in protein 
synthesis. One striking finding of this study, was the flagrant decrease of plasma Mstn 
concentrations in cachectic C26 mice. Since Mstn is a negative regulator of muscle growth [39, 
40], the loss of skeletal muscle in response to catabolic stimuli during cachexia could lead to a, 
protective, down-regulation of systemic Mstn levels. Moreover, as Mstn is mainly produced and 
secreted by skeletal muscle [41], it is expected that Mstn levels will decline in response to muscle 
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mass decrease. This interpretation is coherent with our data showing a positive correlation 
between plasma Mstn concentrations and skeletal muscle mass. Such results are in line with a 
recent study reporting a decrease in plasma Mstn levels in cachectic patients with lung or 
colorectal cancer [42].  
Redox imbalance and chronic OS were found in cancer patients, notably in those with colon 
cancer [43]. Others have found that protein degradation in skeletal muscle was mediated through 
the up-regulation of proteasome subunits and this was an OS-dependent mechanism [15]. Muscle 
oxidative damages were increased only in supplemented mice, without any change in the 
expression of MnSOD and CuZnSOD. On the other hand, catalase expression was up-regulated 
but seemed ineffective and insufficient to counteract muscle OS. We speculate that antioxidants 
provoked an unbalance in the redox state within muscle in favor of OS, thus creating a favorable 
microenvironment for the development and enhancement of muscle wasting. Furthermore, both 
C26 experimental groups exhibited systemic OS but the decrease in total antioxidants capacities 
was observed in supplemented mice only. This decrease, could be attributed to either, a pro-
oxidant effect produced synergistically by the antioxidants cocktail or the consumption of 
antioxidants by another tissue, like tumor.  
Although, tumor weights were similar in both C26 groups, this do not rule out the possibility that 
tumor of supplemented mice has developed faster, since they died earlier. Also it is plausible that 
the premature death of supplemented mice was tumor-dependent. Interestingly, we found that the 
percentage of tumor proliferating cells was greater in supplemented group and this was associated 
with a depression of p21 expression, suggesting that antioxidants have abolished potent stimuli 
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for p21 induction and cell cycle arrest. All these elements plead in favor of an enhancement of 
tumor growth in supplemented mice. Interestingly, we found that 4-HNE deceased exclusively 
within tumor in response to antioxidant supplementation. Clinically, variable amounts of lipid 
peroxidation products were found in colorectal cancer tissues of patients [44] and the decrease in 
HNE levels was positively associated with tumor proliferation [45]. In order to provide 
explanations about the selective decrease of oxidative damage within tumor, we attempted to 
propose antioxidant compounds that could be potentially more problematical in our cachexia 
model. Our mixture contained mainly polyphenols, vitamin E and C. Recently, Sayin et al have 
elegantly demonstrated that supplementation with vitamin E accelerated lung cancer progression 
in mice, reduced ROS amounts within tumor and, the subsequent, oxidative damage level [46]. 
Accordingly, Yam and coworkers demonstrated, in a model of mice bearing Lewis Lung 
Carcinoma (LLC), that vitamin E and C reduced the anticancer activity of omega-3 enriched diet 
by decreasing in situ oxidation of fatty acids [47]. Thus, we speculate that vitamin E and C, well-
known to inhibit lipid peroxidation, could be potential candidates responsible for the decrease of 
4-HNE content in C26 tumor of supplemented mice. Other major components of our antioxidant 
mixture were polyphenols, namely, catechins, resveratrol and quercetin. On the one hand 
supplementation with resveratrol does not affect tumor growth and muscle wasting in distinct 
models of cancer cachexia [48]. On the other hand, administration of either catechins or 
quercetin, into cachectic rodent bearing tumor, reduced the magnitude of muscle atrophy and 
tumor weights [49, 50]. It should be highlighted that these studies focused mostly on muscle 
wasting but lacked direct analyzes on tumor proliferation and modulation of systemic and local 
OS. As ROS may exert a double-faced role in cancer [51], antioxidants could be beneficial in 
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other experimental models, despite the deleterious effects observed in this study. For example, 
we have previously shown that dietary antioxidants decreased tumor oxidative damage and 
reduced proliferation in prostate cancer [24]. Thus, inhibition of OS could either enhance or slow 
tumor growth depending on tumor type/localization.  
One of the limitations of our study was the identification of the antioxidant compound 
responsible for the acceleration of cachexia development. At the same time, we cannot deny the 
fact that using these antioxidants in combination, but not in an isolated manner, is perhaps behind 
the harmful effects observed in mice. We believe that the experimental model employed in the 
present study, could be more reflective to what happening clinically with cancer patients who 
privilege the use of an antioxidant cocktail, as they believe that these compounds are natural and 
safe. The usefulness of antioxidants supplementation in cancer and cancer cachexia remains 
questionable and data emerging from interventions studies are controversial and incoherent [52-
56]. The self-prescribe antioxidants in cancer patients is recurrent and starts to be an alarming 
phenomenon, especially when antioxidants are used randomly and inappropriately. More than 
50% of patients with cancer, increase their consumption of antioxidants complements, without 
medical prescription, after diagnosis of cancer [57]. In the present study, we used an antioxidant 
cocktail available at the European market as “Over The Counter” medicament and doses given to 
mice were adjusted to be adequate with supplier’s recommendations. Another important detail is 
that individual doses of each antioxidant compound were not ultra-physiologic comparing to the 
most of studies conducted on animals. The present study clearly indicates that the daily use of 
antioxidant complements in colon cancer cachexia reduced survival and enhanced cachexia-
associated complications in C26 mice. Patients with cancer, especially those with cachexia, may 
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be more cautious and careful regarding the use of antioxidants, as the prescription of such 
compounds should be done under the credible advice of a nutritionist or cancer patient’s 
physician.  
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FIGURE LEGENDS 
Figure 1. Antioxidant caused premature death of C26-mice. A) Changes in body weight 
during the course of cachexia. B) Median of animal survival determined by the Kaplan-Meier 
method, results are expressed as the percentage of animal survival. C) Food intake measurements 
during the protocol. D) Classification of cachexia severity into “Mild, Moderate or Severe” based 
on total body weight loss and muscle atrophy. Data are mean ± SEM (n=8-10/group). d: 
statistical difference between control and C26-Antiox; e: statistical difference between control 
and C26-PBS.  
Figure 2. C26 inoculation induced muscle wasting in both C26-PBS and C26-Antiox groups. 
A) EDL sections stained with the Gomori method, showing structure of individualized muscle 
fibers; view ×400. B) Fibers diameter measurements. C) Skeletal muscle weights. D) Muscle 
strength. Three trials per animal were performed for each evaluation and the best time of latency 
was retained to calculate the holding impulse. Data are mean ± SEM (n=8-10/group) a: statistical 
difference between control and C26-PBS; b: statistical difference between control and C26-
Antiox; c: statistical difference between C26-PBS and C26-Antiox.  
Figure 3. Antioxidants suppressed Akt activation in skeletal muscle without impacting the 
ubiquitin-proteasome system induction. A) Plasma levels of TNF-α. B) Plasma concentrations 
of Mstn. C) Immunoblot analysis of NF-κB (p65) phosphorylation on Ser 536 and total NF-κB 
(p65) content. D) Immunoblot analysis of the phosphorylated form of Akt on ser 473 and total 
Akt. E) RT-qPCR analysis of the transcript levels of MAFbx and MuRF-1, normalized to the 
reference gene 18S. F) Immunoblot analysis of protein polyubiquitination content. (C-G) All 
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these experiments were performed on gastrocnemius muscles. Data are mean ± SEM (n=8-
10/group) a: statistical difference between control and C26-PBS; b: statistical difference between 
control and C26-Antiox; c: statistical difference between C26-PBS and C26-Antiox.  
Figure 4. Antioxidant supplementation induced muscle oxidative stress. Immunoblot analysis 
of A) protein carbonyls content, B) 4-HNE content and C) the expression of antioxidant defense 
enzymes (MnSOD, CuZnSOD and Catalase). Expression of all proteins was normalized to actin, 
which was used as a load control. (A-C) Data are mean ± SEM (n=8-10/group) a: statistical 
difference between control and C26-PBS; b: statistical difference between control and C26-
Antiox; c: statistical difference between C26-PBS and C26-Antiox.  
Figure 5. Supplemented mice exhibited a reduced systemic antioxidant capacities. A) Plasma 
total antioxidant capacities measured using the ORAC test. Western blotting analysis of B) 
protein carbonyls and C) 4-HNE content in plasma. Data are mean ± SEM (n=8-10/group) a: 
statistical difference between control and C26-PBS; b: statistical difference between control and 
C26-Antiox; c: statistical difference between C26-PBS and C26-Antiox.  
Figure 6. Antioxidants accelerated tumor growth in C26-Antiox mice. A) Tumor weights. B) 
Ki-67 staining on tumor sections; view ×200. C) Percentage of Ki-67 positive nuclei. D) 
Immunoblot analysis of p21 and p27 expression. Immunoblot analysis of E) protein carbonyls 
and F) 4-HNE content. All these experiments were performed on C26-tumors. Hsc-70 was used 
as a load control. Data are mean ± SEM (n=8-10/group) a: statistical difference between control 
and C26-PBS; b: statistical difference between control and C26-Antiox; c: statistical difference 
between C26-PBS and C26-Antiox.  
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Figure S1. Antioxidants did not affect pro-inflammatory cytokines expression within 
skeletal muscle and tumor. RT-qPCR analysis of the transcript levels of TNF-α and IL-6 within 
A) tumor and B) Gastrocnemius tissues, normalized to HPRT1 reference gene. The relative 
expression was calculated using the ΔΔCt method. 
 
Table 1. Composition of antioxidant mixture   
 Nutritional information of antioxidant 
cocktail (mg/kg/day) 
Tea green extracts 11,53 
Included polyphenols 3,46 
Curcumin 8,65 
Quercetin 4,33 
Α-lipoic acid 2,88 
Oligomeric procyanidins 2,88 
Lutein 0,58 
Piperin 0,29 
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Resveratrol 0,14 
Zinc 1,08 
Manganese 0,14 
Selenium 0,0036 
Vitamin A 0,06 
Vitamin C 11,53 
Vitamin E 1,73 
Vitamin B1 0,16 
Vitamin B2 0,20 
Vitamin B3 2,31 
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Highlights 
 Broad range of reactive oxygen species (ROS) is involved in the pathophysiology of 
cachexia-related muscle wasting 
 We supposed that a combination of dietary antioxidants including: catechins, quercetin 
and vitamin C could target a large spectrum of ROS and narrow their detrimental effects 
 In a model of C26 tumor-bearing mice, we showed that antioxidant supplementation, 
caused premature death, enhanced tumor growth and failed to prevent systemic 
inflammation and skeletal muscle atrophy 
 The usefulness of antioxidant in cancer prevention remain questionable and arouses much 
controversy  
 Our data indicate that antioxidant supplementation could be deleterious in colon cancer 
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